TissueTech Grows Salesforce to Support Footprint Expansion
TissueTech, which applies cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. The recently hired sales representatives and associate sales representatives enrolled in TissueTech's newly created mentorship program will support organizational growth under the oversight of Brandon Caraway, Vice President of Sales.
TissueTech leadership stated that it remains optimistic about its trajectory and has expanded its salesforce accordingly. This latest round of hiring substantiates a nationwide trend toward moving many minimally invasive surgical procedures to outpatient settings, as published in a study conducted by KNG Health Consulting. This study showed that in the coming years, between 2019 to 2028, the projected total Medicare savings generated by ambulatory surgery centers could be $73.4 billion.1
Amy Tseng, President and Chief Executive Officer of TissueTech, cites the advent of value-based care that emphasizes health care cost-containment as a factor contributing to the organization's recent expansion and a subsequent need to grow its salesforce. "Our human birth tissue-engineered products are ideally suited for the outpatient environment. During the past 18 months, we have seen an exponential rise in the number of providers adopting our platform technology as a viable treatment to facilitate regenerative healing," Ms. Tsend said.